ReviewWorld journal of surgical oncology2025
Deciphering pancreatobiliary intraductal oncocytic papillary neoplasms: integrative analysis of histomorphologic patterns, immunophenotypic markers, and emerging molecular biomarkers.
Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- When Clinical Suspicion Overrides Benign Biopsy: Invasive Pancreatic Intraductal Oncocytic Papillary Neoplasm With Concurrent Neuroendocrine Tumor.ACG case reports journal · 2026Article
- FusionCancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe reviewed recent advancements in the characterization of intraductal oncocytic papillary neoplasm (IOPN) of the pancreas, with a specific focus on developments in immunohistochemical markers, molecular pathology, and pathogenic mechanisms over the past ten years (2015-2024). Through comprehensive analysis of current literature, we aimed to elucidate the evolving understanding of IOPN's biological behavior and diagnostic features, while identifying potential areas for future research in this distinctive pancreatic neoplasm.
methodsEnglish-language articles on IOPN were searched from Pubmed from the first report of IOPN of the pancreas in 2015 to 2024.
resultsSignificant advancements have been achieved in IOPN research. Molecular investigations discover several immunohistochemical markers which may facilitate the diagnosis of IOPN, including CD117, HepPar-1. Significantly ATP1B1::PRKACA, DNAJB1::PRKACA and ATP1B1::PRKACB gene fusions are identified as molecular hallmarks of IOPN. These genetic alterations are believed to activate the cAMP-PKA signaling pathway, subsequently influencing mitochondrial substrates and contributing to the development of oncocytic features. The molecular signature not only enhances diagnostic specificity but also presents potential therapeutic targets. Furthermore, IOPN exhibits a unique tumor immune microenvironment characterized by elevated PD-L1 expression and substantial inflammatory cell infiltration. The invasive component showed decrease in CD4 + T cells and increase in CD8 + T cells and macrophages suggested the existence of an active immune surveillance, which partially explained why IOPN could have a better prognosis.
conclusionsIOPN exhibits distinct genetic alterations and a unique immune microenvironment. These features not only elucidate the mechanism underlying the relatively favorable prognosis of IOPN and IOPN-derived pancreatic cancers but also offer novel insights into immune regulation strategies for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.